Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Vaylen vs Kova

Both scored on the same six-factor Match Score. Vaylen wins this matchup with a 87 to 46 edge.

Higher Match Score

Vaylen

#8 · Grade B+

People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Visit Vaylen
VS

Kova

#485 · Grade C

People who want a GLP-1 plan bundled with a tracking app and will pay a premium for it.

Visit Kova

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
21
Speed to Start
88
54
Formulary Match
94
40
Support Level
86
68
Flexibility
86
25
Transparency
88
72

Price, coverage & formulary

DetailVaylenKova
Semaglutide$179/moNot disclosed
Tirzepatide$239/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjectable only
Match Score87 · B+46 · C
Winner: Vaylen

Vaylen edges out Kova, 87 to 46 on the default Match Score. One of the widest formularies on the board — both molecules, an oral route, and brand access, all nationwide.

Kova is still a fair pick if its strengths line up with yours — best for: People who want a GLP-1 plan bundled with a tracking app and will pay a premium for it.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Vaylen reviewFull Kova review

More head-to-heads

Or browse alternatives to Vaylen and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.